TVTX — Travere Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $625.78m
- $562.43m
- $145.24m
Annual income statement for Travere Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 175 | 198 | 132 | 109 | 145 |
| Cost of Revenue | |||||
| Gross Profit | 170 | 192 | 128 | 105 | 134 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 313 | 374 | 331 | 437 | 533 |
| Operating Profit | -137 | -176 | -199 | -327 | -388 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -146 | -189 | -217 | -331 | -376 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -146 | -189 | -217 | -331 | -376 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -146 | -169 | -180 | -278 | -111 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -146 | -169 | -180 | -278 | -111 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.11 | -1.93 | -3.63 | -5.12 | -4.97 |